Association between Functional Inhibitors of Acid Sphingomyelinase and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: results from an observational multicenter study
ABSTRACT Several medications commonly used for a number of medical conditions share a property of functional inhibition of acid sphingomyelinase (ASM), or FIASMA. Preclinical and clinical evidence suggest that the (ASM)/ceramide system may be central to SARS-CoV-2 infection. We examined the potential usefulness of FIASMA use among patients hospitalized for severe COVID-19 in an observational multicenter retrospective study conducted at Greater Paris University hospitals. Of 2,846 adult patients hospitalized for severe COVID-19, 277 (9.7%) were taking a FIASMA medication at the time of their hospital admission. The primary endpoint was a composite of intubation and/or death. We compared this endpoint between patients taking vs. not taking a FIASMA medication in time-to-event analyses adjusted for sociodemographic characteristics and medical comorbidities. The primary analysis was a Cox regression model with inverse probability weighting (IPW). Over a mean follow-up of 9.2 days (SD=12.5), the primary endpoint occurred in 104 patients (37.5%) who were taking a FIASMA medication, and 1,060 patients (41.4%) who were not. Taking a FIASMA medication was associated with reduced likelihood of intubation or death in both crude (HR=0.71; 95%CI=0.58-0.87; p<0.001) and the primary IPW (HR=0.58; 95%CI=0.46-0.72; p<0.001) analyses. This association remained significant in multiple sensitivity analyses and was not specific to one FIASMA class or medication. These results show the potential importance of the ASM/ceramide system as a treatment target in COVID-19. Double-blind controlled randomized clinical trials of these medications for COVID-19 are needed..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hoertel, Nicolas [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
doi: |
10.1101/2021.02.22.21252209 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XBI020023375 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XBI020023375 | ||
003 | DE-627 | ||
005 | 20240424104848.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210301s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2021.02.22.21252209 |2 doi | |
035 | |a (DE-627)XBI020023375 | ||
035 | |a (biorXiv)10.1101/2021.02.22.21252209 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hoertel, Nicolas |e verfasserin |0 (orcid)0000-0002-7890-1349 |4 aut | |
245 | 1 | 0 | |a Association between Functional Inhibitors of Acid Sphingomyelinase and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: results from an observational multicenter study |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a ABSTRACT Several medications commonly used for a number of medical conditions share a property of functional inhibition of acid sphingomyelinase (ASM), or FIASMA. Preclinical and clinical evidence suggest that the (ASM)/ceramide system may be central to SARS-CoV-2 infection. We examined the potential usefulness of FIASMA use among patients hospitalized for severe COVID-19 in an observational multicenter retrospective study conducted at Greater Paris University hospitals. Of 2,846 adult patients hospitalized for severe COVID-19, 277 (9.7%) were taking a FIASMA medication at the time of their hospital admission. The primary endpoint was a composite of intubation and/or death. We compared this endpoint between patients taking vs. not taking a FIASMA medication in time-to-event analyses adjusted for sociodemographic characteristics and medical comorbidities. The primary analysis was a Cox regression model with inverse probability weighting (IPW). Over a mean follow-up of 9.2 days (SD=12.5), the primary endpoint occurred in 104 patients (37.5%) who were taking a FIASMA medication, and 1,060 patients (41.4%) who were not. Taking a FIASMA medication was associated with reduced likelihood of intubation or death in both crude (HR=0.71; 95%CI=0.58-0.87; p<0.001) and the primary IPW (HR=0.58; 95%CI=0.46-0.72; p<0.001) analyses. This association remained significant in multiple sensitivity analyses and was not specific to one FIASMA class or medication. These results show the potential importance of the ASM/ceramide system as a treatment target in COVID-19. Double-blind controlled randomized clinical trials of these medications for COVID-19 are needed. | ||
650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
700 | 1 | |a Sánchez-Rico, Marina |e verfasserin |4 aut | |
700 | 1 | |a Gulbins, Erich |e verfasserin |4 aut | |
700 | 1 | |a Kornhuber, Johannes |e verfasserin |4 aut | |
700 | 1 | |a Carpinteiro, Alexander |e verfasserin |4 aut | |
700 | 1 | |a Lenze, Eric J. |e verfasserin |4 aut | |
700 | 1 | |a Reiersen, Angela M. |e verfasserin |4 aut | |
700 | 1 | |a Abellán, Miriam |e verfasserin |4 aut | |
700 | 1 | |a de la Muela, Pedro |e verfasserin |4 aut | |
700 | 1 | |a Vernet, Raphaël |e verfasserin |4 aut | |
700 | 1 | |a Blanco, Carlos |e verfasserin |4 aut | |
700 | 1 | |a Beeker, Nathanaël |e verfasserin |4 aut | |
700 | 1 | |a Neuraz, Antoine |e verfasserin |4 aut | |
700 | 1 | |a Gorwood, Philip |e verfasserin |4 aut | |
700 | 1 | |a Alvarado, Jesús M. |e verfasserin |4 aut | |
700 | 1 | |a Meneton, Pierre |e verfasserin |4 aut | |
700 | 1 | |a Limosin, Frédéric |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
856 | 4 | 0 | |u https://doi.org/10.1038/s41398-022-01804-5 |x 0 |z lizenzpflichtig |3 Volltext |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.02.22.21252209 |x 0 |z kostenfrei |3 Volltext |
912 | |a GBV_XBI | ||
951 | |a AR | ||
952 | |j 2024 |b 23 |c 04 |